IOPtima, the Israeli developer of a laser-based surgical device for reducing intra ocular pressure (IOP) for the treatment of glaucoma, successfully completed and analyzed the results of its first 12-month follow-up period of human clinical trials conducted in Mexico and India.

IOPtima’s laser-based technology enables eye surgeons to perform a simple and safe surgery and reduce IOP without penetrating the eye membrane.

Study results showed the following results:

• The combined results of the study in Mexico and India demonstrated an average reduction of 43% in IOP from 25.5 mmHg’ pre procedure to 14.6 mmHg’ after 12 months follow-up.
• In addition, the Company’s procedure reduced the number of medications taken by the treated patients from 2.6 medications to 0.6, on average.
• These results reflect a Qualified success, (i.e. IOP of less than 18 mmHg’, regardless of medication) of 95% of those treated in the study, and Complete success, (i.e. IOP of less then 18 mmHg’ with no additional medications), of 67%.

Read ^[1] the full release.